Permanent Capital Management LP Makes New Investment in Aura Biosciences, Inc. $AURA

Permanent Capital Management LP bought a new position in shares of Aura Biosciences, Inc. (NASDAQ:AURA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 147,769 shares of the company’s stock, valued at approximately $913,000. Permanent Capital Management LP owned 0.24% of Aura Biosciences as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in AURA. Tower Research Capital LLC TRC boosted its position in shares of Aura Biosciences by 49.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after purchasing an additional 2,104 shares in the last quarter. Invesco Ltd. purchased a new position in Aura Biosciences during the second quarter valued at $76,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Aura Biosciences by 24.3% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,453 shares of the company’s stock valued at $78,000 after buying an additional 2,434 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Aura Biosciences by 286.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,499 shares of the company’s stock worth $85,000 after buying an additional 10,007 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Aura Biosciences in the 2nd quarter worth about $102,000. Institutional investors own 96.75% of the company’s stock.

Insider Activity at Aura Biosciences

In related news, CTO Mark Plavsic sold 12,169 shares of Aura Biosciences stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $6.35, for a total value of $77,273.15. Following the completion of the sale, the chief technology officer directly owned 197,287 shares in the company, valued at approximately $1,252,772.45. This trade represents a 5.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Janet Jill Hopkins sold 17,109 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $5.42, for a total value of $92,730.78. Following the completion of the transaction, the insider directly owned 252,685 shares of the company’s stock, valued at approximately $1,369,552.70. This trade represents a 6.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 39,223 shares of company stock valued at $233,155. 6.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Evercore ISI assumed coverage on shares of Aura Biosciences in a research report on Tuesday, November 25th. They set an “outperform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Aura Biosciences Stock Performance

Shares of AURA stock opened at $5.87 on Monday. The company has a market capitalization of $372.75 million, a price-to-earnings ratio of -3.03 and a beta of 0.44. Aura Biosciences, Inc. has a one year low of $4.34 and a one year high of $8.60. The company’s 50-day moving average is $5.95 and its 200 day moving average is $6.26.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Thursday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.06. As a group, research analysts predict that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.